Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
Oncternal Therapeutics, Inc. (GTXI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results - Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitors - Dosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma - Cash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term investments and no debt as of June 30, 2023 - Management to host webcast today at 5:00 pm ET SAN DIEGO, August 10, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutic..." |
|
| 05/04/2023 |
8-K
| Quarterly results|
Docs:
|
"Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results - Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 - Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor , with expected IND submission in mid-2023 - Cash runway extended into 2025, with $54.3 million in cash, cash equivalents and short-term investments and no debt as of March 31, 2023 - Management to host webcast today at 5:00 pm ET SAN DIEGO, May 4, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported f..." |
|
| 03/09/2023 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Oncternal Therapeutics, Inc. Condensed Consolidated Balance Sheets Data June 30, 2022 December 31, 2021 Cash and cash equivalents $ 78,900 $ 90,765 Total assets 81,526 93,585 Total liabilities 7,525 5,465 Accumulated deficit Total stockholders’ equity 74,001 88,120 Oncternal Therapeutics, Inc. Condensed Consolidated Statements of Operations Data Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Grant revenue $ 191 $ 883 $ 937 $ 1,631 Operating expenses: Research and development 8,761 5,192 15,740 9,105 General and administrative 3,225 3,381 6,904 6,174 Total operating expenses 11,986 8,573 22,644 15,279 Loss from operations Interest income 54 8 62 18 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares outstanding, basic and dilu..." |
|
| 05/05/2022 |
8-K
| Quarterly results |
| 03/10/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/04/2020 |
8-K
| Quarterly results|
Docs:
|
"Rare Pediatric Disease Designation received from FDA for TK216 for treatment of Ewing sarcoma • Interim Phase 1 data for TK216 in 15 evaluable patients with relapsed/refractory Ewing sarcoma demonstrated two complete responses, with no relapses after complete response • Strengthened the balance sheet by securing $10.1 million in equity financing during Q3 2020 SAN DIEGO, November 4, 2020 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2020 financial results. “In the third quarter we continued advancing our oncology pipeline while strengthening our balance sheet,” said James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal. “We e..." |
|
| 08/06/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 03/16/2020 |
8-K
| Quarterly results |
| 11/07/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 10/22/2018 |
8-K
| Quarterly results |
| 08/14/2018 |
8-K
| Quarterly results |
| 05/15/2018 |
8-K
| Quarterly results |
| 03/12/2018 |
8-K
| Quarterly results |
| 11/15/2017 |
8-K
| Quarterly results |
| 08/14/2017 |
8-K
| Quarterly results |
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 03/15/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 08/09/2016 |
8-K
| Quarterly results |
| 05/10/2016 |
8-K
| Quarterly results |
| 03/03/2016 |
8-K
| Quarterly results |
| 11/12/2013 |
8-K
| Quarterly results |
| 05/03/2013 |
8-K
| Quarterly results |
| 02/21/2013 |
8-K
| Quarterly results |
| 11/08/2012 |
8-K
| Quarterly results |
| 05/08/2012 |
8-K
| Form 8-K - Current report |
| 02/21/2012 |
8-K
| Form 8-K - Current report |
|
|
|